Projects
- Basic
- Population
- Clinical
The Basic Science Project aims to elucidate basic, biological mechanisms of sedentary behavior-associated cardiovascular disease (CVD) risk. The Basic Science Project will assess candidate biomarkers by which sedentary behavior (SB) promotes CVD risk and impairs healthy aging. Our model is that extensive time spent sitting causes perturbations in mitochondrial and endothelial dysfunction via sub-optimal blood flow and reduced muscle engagement in the lower extremities. These perturbations influence biomarkers and transducers of CVD risk. The Basic Science Project will leverage biomarker and behavior data generated in the Clinical Project and pre-existing in the Population Project cohort to evaluate known and novel associations of SB with CVD risk in postmenopausal Latina women. The Basic Science Project will facilitate the integration of biomarker and objective SB measures from the Clinical and Population Project. The Clinical Project will randomize 250 sedentary, postmenopausal Latinas who have CVD risk factors, including borderline hypertension and BMI 27.0-45.0 kg/m2, to complete a 3-month study period of either A) control, healthy aging advice or B) intensive intervention aimed to reduce daily sitting time by 25%. The Basic Science Project will conduct analyses of blood samples collected at baseline and follow-up in the Clinical Project.
We hypothesize that biomarkers associated with CVD risk, including biomarkers of glucoregulation and lipid metabolism, mitochondrial and endothelial functioning, will be beneficially changed in the reduced sitting time intervention group but not in the control group.1. Novel biomarkers
1a. Mitochondrial function metabolomics. Approach: We will use state-of-the-art, targeted metabolomic analyses to measure concentrations of ~300 plasma metabolites (e.g., amino acids, acylcarnitines, organic acids) at baseline and follow-up for all Clinical Project participants. We hypothesize that changes in these CVD risk-associated metabolites reflecting improved mitochondrial functioning will be observed in the reduced sitting time intervention group but not observed in the control group.
1b. Epigenetic DNA methylation profiling. Approach: We will conduct targeted DNA methylation profiling of peripheral blood monocytes (PBMC) and determine Apparent Methylomic Aging Rate (AMAR) at baseline and follow-up for all Clinical Project participants. We hypothesize that AMAR will be diminished in the reduced sitting time intervention group and unchanged in the control group.
1c. Epigenetic miRNA expression profiling and identification of candidate cell-cell communication transducers (Sub-study). Approach: We will characterize baseline and follow-up miRNA profiles in plasma and PBMC isolated from 50 control group participants and 50 "best behavioral responder" intervention group participants from the Clinical Project. We will identify SB-associated miRNAs that are specifically altered in the reduced sitting time intervention group and not the control group. We will select and conduct in vitro cell-based, mechanistic studies on 2-4 miRNA candidate transducers of sitting time. We hypothesize that specific miRNAs will be altered after 3 months in the "best responder" intervention group but unchanged in the control group and that these miRNAs can transduce effects on cellular functioning that are related to CVD risk.
2. Standard biomarkers
2a. Vascular environment and endothelial function. Approach: We will measure plasma biomarkers of systemic inflammation (C-reactive protein (CRP)), endothelial cell adhesiveness and activation (vascular adhesion molecule 1 (sVCAM-1), intercellular adhesion molecule 1 (sICAM-1), P- and E-selectins), oxidative stress (F2-isoprostane), and coagulation (fibrinogen) at baseline and follow-up for all Clinical Project participants. We hypothesize that these biomarkers will be diminished in the reduced sitting time intervention group and unchanged in the control group.
2b. Glucose regulation and lipid metabolism. Approach: We will measure fasting plasma insulin, glucose, and lipid panel components and hemoglobin A1c (HbA1c) at baseline and follow-up for all Clinical Project participants. We hypothesize that glucose regulation and lipid metabolism will be improved in the reduced sitting time intervention group and unchanged in the control group.
Summary: The Basic Science Project will concurrently assess novel and standard candidate biomarkers of CVD risk that can shed light on basic, biological mechanisms not evaluated previously in SB research and in a high-risk Latina population that has not been the specific target of any SB intervention study. The Basic Science Project is highly integrated with the Clinical Project. The Basic Science Project team will also contribute to statistical biomarker data analyses conducted by the Shared Resource Core that will integrate behavioral outcomes from both the Clinical and Population Projects. Findings from the Basic Science Project will further our understanding of the effects and effectors of SB on women's cardiovascular health and inform future studies.